Unió Europea - espanyol - EMA (European Medicines Agency)

acorda therapeutics ireland limited - la levodopa - mal de parkinson - medicamentos contra el parkinson - inbrija está indicado para el tratamiento intermitente de episodios de las fluctuaciones motoras (episodios) en pacientes adultos con enfermedad de parkinson (ep) tratados con levodopa/dopa-descarboxilasa inhibidor de la.

Unió Europea - espanyol - EMA (European Medicines Agency)

nektar therapeutics uk limited - etirinotecan pegol - neoplasias de la mama - agentes antineoplásicos - tratamiento del cáncer de mama con metástasis cerebrales.

Unió Europea - espanyol - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibacterianos para uso sistémico, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.

Unió Europea - espanyol - EMA (European Medicines Agency)

heron therapeutics, b.v. - bupivacaine, meloxicam - dolor, postoperatorio - anestésicos - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.

Unió Europea - espanyol - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - agentes antineoplásicos - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Unió Europea - espanyol - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - otras drogas del sistema nervioso - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Unió Europea - espanyol - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mieloma múltiple - agentes antineoplásicos - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Unió Europea - espanyol - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - inmunosupresores - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Perú - espanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

novamedis peru s.a.c. -

Perú - espanyol - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

novamedis peru s.a.c. -